Brokers Issue Forecasts for AxoGen FY2029 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of AxoGen in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky anticipates that the medical equipment provider will post earnings of $0.38 per share for the year. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group upped their target price on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday.

AxoGen Price Performance

Shares of NASDAQ AXGN opened at $19.43 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The firm has a market capitalization of $855.08 million, a PE ratio of -60.72 and a beta of 1.00. AxoGen has a 1-year low of $5.55 and a 1-year high of $21.00. The business’s fifty day moving average price is $17.66 and its two-hundred day moving average price is $14.99.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in AxoGen in the fourth quarter worth approximately $30,000. US Bancorp DE bought a new stake in shares of AxoGen in the 4th quarter worth $30,000. State of Wyoming acquired a new stake in shares of AxoGen in the fourth quarter valued at $31,000. Quest Partners LLC boosted its stake in AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 2,076 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in AxoGen during the fourth quarter valued at about $93,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.